{"schema_version":"secwatch.filing_event.v1","accession":"0001048477-24-000132","form_type":"8-K","ticker":"BMRN","cik":"0001048477","company_name":"BIOMARIN PHARMACEUTICAL INC","filed_at":"2024-08-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.016597+00:00","generated_at":"2026-05-31T07:06:08.616678+00:00","sec_items":["2.05"],"event_type":"other_material","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"BioMarin to cut ~225 jobs, incur $30-35M in severance costs by end of 2024","bullets":["Workforce reduction of ~225 employees committed on Aug 23, 2024, in organizational redesign.","Estimated pre-tax charges of $30-35M for severance and termination benefits, mostly in H2 2024.","Plan follows updated ROCTAVIAN strategy and discontinuation of BMN 293 development announced Aug 5, 2024.","Notifications completed by Aug 28, 2024; reductions expected substantially complete by end of 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001048477-24-000132","json":"https://secwatch.observer/filing/0001048477-24-000132.json","markdown":"https://secwatch.observer/filing/0001048477-24-000132.md","text":"https://secwatch.observer/filing/0001048477-24-000132.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1048477/000104847724000132/0001048477-24-000132-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1048477/000104847724000132/bmrn-20240823.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T07:06:08.616678+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}